ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Research Report 2025
Published Date: September 2025
|
Report Code: QYRE-Auto-25A16539
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Neuromyelitis Optica Spectrum Disorders NMOSD Market Research Report 2024
BUY CHAPTERS

Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Research Report 2025

Code: QYRE-Auto-25A16539
Report
September 2025
Pages:85
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Roche
Pfizer Inc
Fresenius
TEVA
Sandoz Inc
Intas
Nang Kuang Pharmaceutical
Tianjin King York
Baxter
CSL Limited
Grifols S A
Octapharma AG

Neuromyelitis Optica Spectrum Disorders (NMOSD) Market

The global market for Neuromyelitis Optica Spectrum Disorders (NMOSD) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Neuromyelitis optica (NMO), also known as Devic"s disease, is a rare condition where the immune system damages the spinal cord and the nerves of the eyes (optic nerves).NMO can affect anyone at any age, but it"s more common in women than men.
North American market for Neuromyelitis Optica Spectrum Disorders (NMOSD) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Neuromyelitis Optica Spectrum Disorders (NMOSD) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Neuromyelitis Optica Spectrum Disorders (NMOSD) in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Neuromyelitis Optica Spectrum Disorders (NMOSD) include Roche, Pfizer, Fresenius, Teva, Sandoz, Intas, Nang Kuang Pharmaceutical, Tianjin King York, Baxter, CSL, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Neuromyelitis Optica Spectrum Disorders (NMOSD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neuromyelitis Optica Spectrum Disorders (NMOSD).
The Neuromyelitis Optica Spectrum Disorders (NMOSD) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Neuromyelitis Optica Spectrum Disorders (NMOSD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neuromyelitis Optica Spectrum Disorders (NMOSD) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Report

Report Metric Details
Report Name Neuromyelitis Optica Spectrum Disorders (NMOSD) Market
Segment by Type
  • Relapsing Form
  • Monophasic Form
Segment by Application
  • Hospital
  • Clinic
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Roche, Pfizer, Fresenius, Teva, Sandoz, Intas, Nang Kuang Pharmaceutical, Tianjin King York, Baxter, CSL, Grifols, Octapharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Neuromyelitis Optica Spectrum Disorders (NMOSD) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Neuromyelitis Optica Spectrum Disorders (NMOSD) Market report?

Ans: The main players in the Neuromyelitis Optica Spectrum Disorders (NMOSD) Market are Roche, Pfizer, Fresenius, Teva, Sandoz, Intas, Nang Kuang Pharmaceutical, Tianjin King York, Baxter, CSL, Grifols, Octapharma

What are the Application segmentation covered in the Neuromyelitis Optica Spectrum Disorders (NMOSD) Market report?

Ans: The Applications covered in the Neuromyelitis Optica Spectrum Disorders (NMOSD) Market report are Hospital, Clinic

What are the Type segmentation covered in the Neuromyelitis Optica Spectrum Disorders (NMOSD) Market report?

Ans: The Types covered in the Neuromyelitis Optica Spectrum Disorders (NMOSD) Market report are Relapsing Form, Monophasic Form

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Relapsing Form
1.2.3 Monophasic Form
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Perspective (2020-2031)
2.2 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Growth Trends by Region
2.2.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Neuromyelitis Optica Spectrum Disorders (NMOSD) Historic Market Size by Region (2020-2025)
2.2.3 Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Region (2026-2031)
2.3 Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Dynamics
2.3.1 Neuromyelitis Optica Spectrum Disorders (NMOSD) Industry Trends
2.3.2 Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Drivers
2.3.3 Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Challenges
2.3.4 Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Spectrum Disorders (NMOSD) Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Spectrum Disorders (NMOSD) Players by Revenue (2020-2025)
3.1.2 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue Market Share by Players (2020-2025)
3.2 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue
3.4 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue in 2024
3.5 Global Key Players of Neuromyelitis Optica Spectrum Disorders (NMOSD) Head office and Area Served
3.6 Global Key Players of Neuromyelitis Optica Spectrum Disorders (NMOSD), Product and Application
3.7 Global Key Players of Neuromyelitis Optica Spectrum Disorders (NMOSD), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Spectrum Disorders (NMOSD) Breakdown Data by Type
4.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Historic Market Size by Type (2020-2025)
4.2 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Type (2026-2031)
5 Neuromyelitis Optica Spectrum Disorders (NMOSD) Breakdown Data by Application
5.1 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Historic Market Size by Application (2020-2025)
5.2 Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (2020-2031)
6.2 North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2020-2025)
6.4 North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (2020-2031)
7.2 Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2020-2025)
7.4 Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (2020-2031)
8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (2020-2025)
8.4 Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (2020-2031)
9.2 Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2020-2025)
9.4 Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (2020-2031)
10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2020-2025)
10.4 Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.1.4 Roche Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.1.5 Roche Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.2.4 Pfizer Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.2.5 Pfizer Recent Development
11.3 Fresenius
11.3.1 Fresenius Company Details
11.3.2 Fresenius Business Overview
11.3.3 Fresenius Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.3.4 Fresenius Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.3.5 Fresenius Recent Development
11.4 Teva
11.4.1 Teva Company Details
11.4.2 Teva Business Overview
11.4.3 Teva Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.4.4 Teva Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.4.5 Teva Recent Development
11.5 Sandoz
11.5.1 Sandoz Company Details
11.5.2 Sandoz Business Overview
11.5.3 Sandoz Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.5.4 Sandoz Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.5.5 Sandoz Recent Development
11.6 Intas
11.6.1 Intas Company Details
11.6.2 Intas Business Overview
11.6.3 Intas Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.6.4 Intas Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.6.5 Intas Recent Development
11.7 Nang Kuang Pharmaceutical
11.7.1 Nang Kuang Pharmaceutical Company Details
11.7.2 Nang Kuang Pharmaceutical Business Overview
11.7.3 Nang Kuang Pharmaceutical Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.7.4 Nang Kuang Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.7.5 Nang Kuang Pharmaceutical Recent Development
11.8 Tianjin King York
11.8.1 Tianjin King York Company Details
11.8.2 Tianjin King York Business Overview
11.8.3 Tianjin King York Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.8.4 Tianjin King York Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.8.5 Tianjin King York Recent Development
11.9 Baxter
11.9.1 Baxter Company Details
11.9.2 Baxter Business Overview
11.9.3 Baxter Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.9.4 Baxter Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.9.5 Baxter Recent Development
11.10 CSL
11.10.1 CSL Company Details
11.10.2 CSL Business Overview
11.10.3 CSL Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.10.4 CSL Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.10.5 CSL Recent Development
11.11 Grifols
11.11.1 Grifols Company Details
11.11.2 Grifols Business Overview
11.11.3 Grifols Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.11.4 Grifols Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.11.5 Grifols Recent Development
11.12 Octapharma
11.12.1 Octapharma Company Details
11.12.2 Octapharma Business Overview
11.12.3 Octapharma Neuromyelitis Optica Spectrum Disorders (NMOSD) Introduction
11.12.4 Octapharma Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
11.12.5 Octapharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Roche
Pfizer Inc
Fresenius
TEVA
Sandoz Inc
Intas
Nang Kuang Pharmaceutical
Tianjin King York
Baxter
CSL Limited
Grifols S A
Octapharma AG
List of Tables
 Table 1. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Relapsing Form
 Table 3. Key Players of Monophasic Form
 Table 4. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Region (2020-2025)
 Table 8. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Region (2026-2031)
 Table 10. Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Trends
 Table 11. Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Drivers
 Table 12. Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Challenges
 Table 13. Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Restraints
 Table 14. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Players (2020-2025)
 Table 16. Global Top Neuromyelitis Optica Spectrum Disorders (NMOSD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) as of 2024)
 Table 17. Ranking of Global Top Neuromyelitis Optica Spectrum Disorders (NMOSD) Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Neuromyelitis Optica Spectrum Disorders (NMOSD), Headquarters and Area Served
 Table 20. Global Key Players of Neuromyelitis Optica Spectrum Disorders (NMOSD), Product and Application
 Table 21. Global Key Players of Neuromyelitis Optica Spectrum Disorders (NMOSD), Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue Market Share by Type (2020-2025)
 Table 25. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue Market Share by Type (2026-2031)
 Table 27. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue Market Share by Application (2020-2025)
 Table 29. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue Market Share by Application (2026-2031)
 Table 31. North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Roche Company Details
 Table 47. Roche Business Overview
 Table 48. Roche Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 49. Roche Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 50. Roche Recent Development
 Table 51. Pfizer Company Details
 Table 52. Pfizer Business Overview
 Table 53. Pfizer Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 54. Pfizer Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 55. Pfizer Recent Development
 Table 56. Fresenius Company Details
 Table 57. Fresenius Business Overview
 Table 58. Fresenius Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 59. Fresenius Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 60. Fresenius Recent Development
 Table 61. Teva Company Details
 Table 62. Teva Business Overview
 Table 63. Teva Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 64. Teva Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 65. Teva Recent Development
 Table 66. Sandoz Company Details
 Table 67. Sandoz Business Overview
 Table 68. Sandoz Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 69. Sandoz Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 70. Sandoz Recent Development
 Table 71. Intas Company Details
 Table 72. Intas Business Overview
 Table 73. Intas Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 74. Intas Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 75. Intas Recent Development
 Table 76. Nang Kuang Pharmaceutical Company Details
 Table 77. Nang Kuang Pharmaceutical Business Overview
 Table 78. Nang Kuang Pharmaceutical Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 79. Nang Kuang Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 80. Nang Kuang Pharmaceutical Recent Development
 Table 81. Tianjin King York Company Details
 Table 82. Tianjin King York Business Overview
 Table 83. Tianjin King York Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 84. Tianjin King York Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 85. Tianjin King York Recent Development
 Table 86. Baxter Company Details
 Table 87. Baxter Business Overview
 Table 88. Baxter Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 89. Baxter Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 90. Baxter Recent Development
 Table 91. CSL Company Details
 Table 92. CSL Business Overview
 Table 93. CSL Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 94. CSL Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 95. CSL Recent Development
 Table 96. Grifols Company Details
 Table 97. Grifols Business Overview
 Table 98. Grifols Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 99. Grifols Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 100. Grifols Recent Development
 Table 101. Octapharma Company Details
 Table 102. Octapharma Business Overview
 Table 103. Octapharma Neuromyelitis Optica Spectrum Disorders (NMOSD) Product
 Table 104. Octapharma Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025) & (US$ Million)
 Table 105. Octapharma Recent Development
 Table 106. Research Programs/Design for This Report
 Table 107. Key Data Information from Secondary Sources
 Table 108. Key Data Information from Primary Sources
 Table 109. Authors List of This Report


List of Figures
 Figure 1. Neuromyelitis Optica Spectrum Disorders (NMOSD) Picture
 Figure 2. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Type: 2024 VS 2031
 Figure 4. Relapsing Form Features
 Figure 5. Monophasic Form Features
 Figure 6. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Application: 2024 VS 2031
 Figure 8. Hospital Case Studies
 Figure 9. Clinic Case Studies
 Figure 10. Neuromyelitis Optica Spectrum Disorders (NMOSD) Report Years Considered
 Figure 11. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 12. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Region: 2024 VS 2031
 Figure 14. Global Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Players in 2024
 Figure 15. Global Top Neuromyelitis Optica Spectrum Disorders (NMOSD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuromyelitis Optica Spectrum Disorders (NMOSD) as of 2024)
 Figure 16. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Spectrum Disorders (NMOSD) Revenue in 2024
 Figure 17. North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 18. North America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Country (2020-2031)
 Figure 19. United States Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. Canada Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Country (2020-2031)
 Figure 23. Germany Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. France Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. U.K. Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Italy Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Russia Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Nordic Countries Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Region (2020-2031)
 Figure 31. China Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Japan Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. South Korea Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Southeast Asia Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. India Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Australia Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Country (2020-2031)
 Figure 39. Mexico Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Brazil Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Share by Country (2020-2031)
 Figure 43. Turkey Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Saudi Arabia Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. UAE Neuromyelitis Optica Spectrum Disorders (NMOSD) Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Roche Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 47. Pfizer Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 48. Fresenius Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 49. Teva Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 50. Sandoz Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 51. Intas Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 52. Nang Kuang Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 53. Tianjin King York Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 54. Baxter Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 55. CSL Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 56. Grifols Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 57. Octapharma Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorders (NMOSD) Business (2020-2025)
 Figure 58. Bottom-up and Top-down Approaches for This Report
 Figure 59. Data Triangulation
 Figure 60. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

Global Neuromyelitis Optica Spectrum Disorder NMOSD Market Research Report 2024
Global Neuromyelitis Optica Drug Market Research Report 2025
Neuromyelitis Optic Spectrum Disorder Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Neuromyelitis Optica Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Drugs for Neuromyelitis Optica Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Devic s Syndrome Neuromyelitis Optica Treatment Market Insights Forecast to 2030
Optic Neuropathy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Multiple Sclerosis Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Demyelinating Diseases Therapeutics Market Research Report 2024
Optic Neuritis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Metachromatic Leukodystrophy Treatment Market Research Report 2025
Global Retinitis Pigmentosa Retinitis Market Insights Forecast to 2030
Global Neurologic Disorders Therapeutics Market Insights Forecast to 2030
Transverse Myelitis Diagonosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Optic Neuritis Drug Market Research Report 2025
Global Neurotrophic Keratitis Treatment Market Insights Forecast to 2030
Transverse Myelitis Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Ischemic Optic Neuropathy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Neurotrophic Keratitis Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neurometabolic Disorders Market Insights Forecast to 2030

RELATED REPORTS

Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13Z8760
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Intracranial Pressure (ICP) Monitoring Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37L4006
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Brain Disease Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12P6151
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3X6389
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions